Table. Overview of randomized phase III studies of adjuvant cisplatin based chemotherapy versus observation in non-small cell lung cancer.

Study	Tumor stage	No of patients	Chemotherapeutic regimen/No of cycles	Median follow-up in months	Median survival in months: chemotherapy versus observation	5 year survival rate: chemotherapy versus observation
ALPI (9)	p I–IIIA	1209	Cisplatin + mitomycin C + vindesine; 3 cycles	64.5	55.2 vs. 48 p = 0.6	No data
BLT (10)	p I–III	381	Cisplatin + mitomycin C + ifosfamide or Cisplatin + mitomycin C + vinblastine or Cisplatin + vindesine or Cisplatin + vinorelbine; 3 cycles	34.6	33.9 vs. 32.6 p = 0.9	No data
IALT (11)	p I–III	1867	Cisplatin + etoposide or Cisplatin + vinorelbine or Cisplatin + vinblastine or Cisplatin + vindesine; 3–4 cycles	56	No data	44.5 % vs. 40.4 % p < 0.03
Intergroup JBR.10 of NCIC (12)	p IB–IIB (without T3NOMO)	482	Cisplatin + vinorelbine; 4 cycles	62	94 vs. 63 p = 0.009	69 % vs. 54 % p = 0.03
ANITA (14)	p IB–IIIA	840	Cisplatin + vinorelbine; 4 cycles	> 70	65.7 vs. 43.7 p = 0.02	51 % vs. 43 % p = 0.02

The pooled analysis (LACE, lung adjuvant cisplatin evaluation) of the data from the 5 studies using cisplatin based chemotherapy (BLT, ALPI, IALT, NCIC JBR.10, ANITA) including 4584 patients showed an absolute 5 year benefit of 4.2% for the patients treated with cisplatin (15).